Complete List of Activities 2020
| Title | Collaboration Type | HHS Participating Agencies | NIH Participating Institutes, Centers, and Offices | Description |
|---|---|---|---|---|
| Industrywide exposure assessment study of workers exposed to graphene and other two-dimensional nanomaterials | Research Initiative | CDC | NIEHS | There have been relatively few studies evaluating the toxicity of 2D nanomaterials and even fewer data are available regarding workplace exposures in the United States. This project will provide real-world exposure data along with important material characteristic information for the interpretation of current and future toxicity and risk assessment studies. |
| Influenza Diagnostics Risk Management Meeting (FRMM) Strategy Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, CDC, FDA | NIAID | Reviewing a draft strategic plan for senior leadership |
| Influenza Risk Management Meeting | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza Risk Management Meetings provide members including the Office of the Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority(BARDA), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH)) with a venue to discuss issues relating to the US Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v. |
| Inter-Agency Working Group on the National Healthcare Quality and Disparities Report | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, IHS, OS | NIMHD, NCI, NHLBI, OD/DPCPSI | This working group provides expert scientific guidance for the National Healthcare Quality and Disparities Report. These annual reports measure trends in effectiveness of care, patient safety, timeliness of care, patient centeredness, and efficiency of care. The reports present, in chart form, the latest available findings on quality of and access to health care. |
| Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG) | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NHGRI, CC, NCATS, NCI, NEI, NHLBI, NIAAA, NICHD, NLM | This education collaborative facilitates sharing interactions among professional societies, agencies, and health systems. It intends to enhance the accrual of knowledge and skill among practitioners applying genomic results to clinical care. In its start-up phase, the ISCC-PEG focused primarily on physicians and dentists. It has since expanded to engage and collaborate with allied practitioner groups such as nurse practitioners, physician assistants, pharmacists, genetic counselors, and nurses comprising integrated health care teams. It will continue to add other relevant professions and add to the reviewed and searchable educational resources on its website. |
| Interagency Adult Literacy Research Group | Committee, Work group, Advisory group, or Task Force | ACF | NICHD | This is an intra-government, trans-agency group shares updates on research relevant to adults with lower literacy skills (i.e., reading and writing) as well as practices and programs that are being implemented to assist these learners in various agencies. The goal is for staff and corresponding agencies to be informed of broader efforts occurring around adult literacy within the federal government and to keep abreast of research and promising programs that might inform their work. |
|
Interagency Agreement NTP/NIEHS and NCTR/FDA (IAA) |
Other | FDA | NIEHS | Collaborative working relationship between NTP/NIEHS and NCTR/FDA |
| Interagency Artificial Pancreas Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NIBIB, NICHD | The Interagency Artificial Pancreas Working Group is a group of multi-disciplined scientists and clinicians from the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) to support the Artificial Pancreas Initiative. The goals of this initiative are to provide infrastructure for narrowing the gap between basic biomedical knowledge and clinical application of novel technologies, and to cross-fertilize and partner with stakeholders in order to identify and overcome the clinical and scientific challenges to the development of an artificial pancreas. Through collaborative efforts, such as workshops, the group strives to develop innovative strategies to achieve their goals. |
| Interagency Autism Coordinating Committee (IACC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIMH, NICHD, NIEHS, NINDS | The Interagency Autism Coordinating Committee (IACC) is a federal advisory committee charged with coordinating federal activities concerning autism spectrum disorder (ASD) and providing advice to the Secretary of Health and Human Services on issues related to autism. Membership of the Committee includes a wide array of federal departments and agencies involved in ASD research and services, as well as public stakeholders, including self-advocates, family members of children and adults with ASD, advocates, service providers, and researchers, who represent a variety of perspectives from within the autism community. The Committee members myriad expertise and experience aim to equip the IACC to address the wide range of issues and challenges faced by individuals and families affected by autism. The IACC was reauthorized under the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2019. The IACC is being reconstituted under the most recent authorization and will resume meeting in 2021. |
| Interagency Biodefense Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, FIC, NIAID, NIEHS, NLM, OD/OM/OB, OD/ORS | Coordinates implementation of the U.S. National Biodefense Strategy and Presidential Memorandum on the Support for Biodefense towards an integrated, comprehensive approach to manage biodefense activities in support of the broader biodefense enterprise. |